Form 4: Fate Therapeutics Director Karin Jooss Granted Stock Options

Director Karin Jooss received stock options for 40,000 shares of Fate Therapeutics (FATE) on June 7, 2024, as part of the company's non-employee director compensation policy.

Summary

• Karin Jooss, a director at Fate Therapeutics, was granted stock options on June 7, 2024.
• The options are for 40,000 shares of Fate Therapeutics common stock.
• The exercise price of the options is $3.68 per share.
• The options vest on the earlier of June 7, 2025, or the date of the Issuer's 2025 Annual Meeting of Stockholders, contingent upon continued service on the Board of Directors.
• The options expire on June 7, 2034.
• The grant was made under the Issuer's Amended and Restated Non-Employee Director Compensation Policy.

Sentiment

Score: 7

Explanation: The document reflects a routine director compensation matter, which is generally viewed neutrally to positively as it aligns director interests with shareholders.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service on the Board of Directors.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Granting stock options to directors is a common practice in the biotechnology industry to align their interests with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Stock option grants to non-employee directors are a standard component of compensation packages in the biotech industry.
• Comparable companies like CRISPR Therapeutics and Editas Medicine also utilize equity grants as part of their director compensation policies.
• The size of the grant (40,000 shares) would need to be compared to the overall compensation packages of directors at similar-sized biotech companies to determine if it is within industry norms.

Stakeholder Impact

• The stock option grant could have a minor dilutive effect on existing shareholders.
• The grant incentivizes the director to act in the best interests of the shareholders.

Key Dates